Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8233 in Japanese Participants With Dyslipidemia
NCT04823611Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD8233 in dyslipidemia (7 arms), sponsored by AstraZeneca. Primary endpoint: Change in LDL-C in Serum at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
AZD8233
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04823611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823611.